Sellas Life Sciences is trading 10.1% down at $10.18 as investors react to perceived delays in the Phase 3 REGAL AML trial data release.
- Traders are focused on timing uncertainty for the pivotal readout, leading to a repricing of risk around the study's binary outcome.
- The downward move reflects profit-taking on recent gains, even as the broader biotech sector shows strength.